Singlera Genomics, a Chinese developer of non-invasive genetic diagnostics, announced on Wednesday the completion of its Series B+ funding round at 300 million yuan ($45 million).
The round was led by Forestone Capital, with participation from Galaxy Yuanhui Investment and Qiandao Investment, among other domestic investors. The publicly-listed Sansure Biotech, which specialises in molecular diagnostics and genetic testing technologies, joined the deal as a strategic investor.